hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06387342, orgStudyIdInfo id: CF102-222PC, briefTitle: Namodenoson Treatment of Advanced Pancreatic Cancer, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-07-15, primaryCompletionDateStruct date: 2026-07-15, completionDateStruct date: 2026-12-15, studyFirstPostDateStruct date: 2024-04-29, lastUpdatePostDateStruct date: 2024-04-29, sponsorCollaboratorsModule leadSponsor name: Can-Fite BioPharma, class: INDUSTRY, descriptionModule briefSummary: This is an open-label trial in patients with advanced pancreatic cancer. The trial will evaluate the safety, clinical activity, and pharmacokinetics of the study drug, namodenoson, in this group of patients., conditionsModule conditions: Pancreatic Adenocarcinoma, conditions: Pancreatic Cancer, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, interventionModelDescription: Open-label study, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 20, type: ESTIMATED, armsInterventionsModule interventions name: Namodenoson 25mg, outcomesModule primaryOutcomes measure: Adverse Events, primaryOutcomes measure: Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) Change from baseline, secondaryOutcomes measure: Objective response rate, secondaryOutcomes measure: Progression free survival, secondaryOutcomes measure: Disease control rate, secondaryOutcomes measure: Duration of response, secondaryOutcomes measure: Overall survival, otherOutcomes measure: Quality of Life evaluation with EORTC QLQ-C30, otherOutcomes measure: Quality of Life evaluation with EORTC QLQ-PAN26, otherOutcomes measure: Pharmacokinetics of namodenoson: Cmax, otherOutcomes measure: Pharmacokinetics of namodenoson: Cmin, otherOutcomes measure: Pharmacokinetics of namodenoson: AUC(0-12), otherOutcomes measure: Cancer antigen 19-9 (CA 19-9), otherOutcomes measure: Carcinoembryonic Antigen (CEA), eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Rabin Medical Center Institute of Oncology, city: Petach Tikva, zip: 49100, country: Israel, contacts name: Salomon M Stemmer, MD, role: CONTACT, geoPoint lat: 32.08707, lon: 34.88747, hasResults: False
protocolSection identificationModule nctId: NCT06387316, orgStudyIdInfo id: 2023-1526, briefTitle: Cephalic Phase Responses to Nutritive and Non-Nutritive Sweeteners, statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2024-03-26, primaryCompletionDateStruct date: 2024-04-17, completionDateStruct date: 2025-03-30, studyFirstPostDateStruct date: 2024-04-29, lastUpdatePostDateStruct date: 2024-04-29, sponsorCollaboratorsModule leadSponsor name: Purdue University, class: OTHER, descriptionModule briefSummary: This study will focus on changes in blood sugar in response to tasting different types of sweeteners using continuous glucose monitoring (CGM) technology., conditionsModule conditions: Pre Diabetes, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: CROSSOVER, primaryPurpose: BASIC_SCIENCE, maskingInfo masking: SINGLE, maskingDescription: solutions are coded, whoMasked: PARTICIPANT, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: No Oral Stimulation, interventions name: Oral water stimulation, interventions name: Oral Salt Stimulation, interventions name: Oral Sucralose Stimulation, interventions name: Oral Sucrose stimulation, outcomesModule primaryOutcomes measure: Blood glucose concentration, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 70 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Purdue University, city: West Lafayette, state: Indiana, zip: 47907, country: United States, geoPoint lat: 40.42587, lon: -86.90807, hasResults: False
protocolSection identificationModule nctId: NCT06387277, orgStudyIdInfo id: RV1551P20220376, briefTitle: Re-epithelialization Efficacy Evaluation of Cosmetic Product RV1551P vs Non-treated Forearm of Healthy Adult Women, statusModule overallStatus: COMPLETED, startDateStruct date: 2022-09-19, primaryCompletionDateStruct date: 2022-12-12, completionDateStruct date: 2022-12-12, studyFirstPostDateStruct date: 2024-04-29, lastUpdatePostDateStruct date: 2024-04-29, sponsorCollaboratorsModule leadSponsor name: Pierre Fabre Dermo Cosmetique, class: INDUSTRY, descriptionModule briefSummary: The aim of this study was to evaluate the impact of the product RV1551P GB3224 on skin microbiota during wound healing process, based on swab samples collected from lesion areas using an epidermally ablated skin model of erbium YAG laser., conditionsModule conditions: Healthy, designModule studyType: OBSERVATIONAL, designInfo observationalModel: OTHER, timePerspective: OTHER, enrollmentInfo count: 21, type: ACTUAL, armsInterventionsModule interventions name: RV1551P GB3224, outcomesModule primaryOutcomes measure: Time to re-epithelialization as assessed by in vivo examination by the investigator and standardized photographs taken with a C Cube Camera®, secondaryOutcomes measure: Skin microbiota diversity from swab samples., secondaryOutcomes measure: Skin microbiota composition from swab samples., secondaryOutcomes measure: Metabolomic analysis from swab samples, eligibilityModule sex: FEMALE, minimumAge: 20 Years, maximumAge: 45 Years, stdAges: ADULT, contactsLocationsModule locations facility: Skin Research Centre, city: Toulouse, state: Haute-Garonne, zip: 31300, country: France, geoPoint lat: 43.60426, lon: 1.44367, hasResults: False
protocolSection identificationModule nctId: NCT06387264, orgStudyIdInfo id: 2022PHC032, briefTitle: Compont - Varicose Veins of the Lower Extremities, statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2023-01-11, primaryCompletionDateStruct date: 2024-04, completionDateStruct date: 2024-12, studyFirstPostDateStruct date: 2024-04-29, lastUpdatePostDateStruct date: 2024-04-29, sponsorCollaboratorsModule leadSponsor name: Peking University People's Hospital, class: OTHER, collaborators name: Peking University First Hospital, collaborators name: The Fourth Affiliated Hospital of Zhejiang University School of Medicine, collaborators name: First Affiliated Hospital Xi'an Jiaotong University, collaborators name: Liaocheng People's Hospital, collaborators name: The Second Affiliated Hospital of Chongqing Medical University, descriptionModule briefSummary: The purpose of this clinical trial is to evaluate the effectiveness and safety of Medical Adhesive produced by Beijing Compont Medical Devices Co., Ltd. in the treatment of varicose veins in the lower extremities.The main questions it aims to answer is: What medical problems do participants have when using tissue glue? Researchers will compare Medical Adhesive to ClosureFast Endovenous Radiofrequency Ablation (RFA) Catheter (produced by Medtronic Inc. to see if Medical Adhesive works to treat varicose veins in the lower extremities.Participants will:Treated with closed varicose veins of the lower extremity by Medical Adhesive or ClosureFast.Return to the hospital at 1, 12, and 24 weeks postoperatively for Doppler ultrasound, and at 4, 12, 24 weeks postoperatively for venous scoring., conditionsModule conditions: Varicose Veins of Lower Limb, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 188, type: ACTUAL, armsInterventionsModule interventions name: Medical Adhesive, interventions name: ClosureFast Endovenous Radiofrequency Ablation(RFA) Catheter, outcomesModule primaryOutcomes measure: Clinical success rate, secondaryOutcomes measure: Technical success rate, secondaryOutcomes measure: Target vascular closure rate at 12 weeks after operation., secondaryOutcomes measure: Clinical signs, secondaryOutcomes measure: Venous Clinical Severity Score (VCSS), secondaryOutcomes measure: Aberdeen Varicose Vein Questionnaire (AVVQ), secondaryOutcomes measure: Operation duration, secondaryOutcomes measure: Evaluation of product performance, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Peking University People's Hospital, city: Beijing, country: China, geoPoint lat: 39.9075, lon: 116.39723, hasResults: False
protocolSection identificationModule nctId: NCT06387238, orgStudyIdInfo id: PSMA-mHSPC, briefTitle: Exploration of the Value of PSMA PET/CT in Dynamic Monitoring of the Efficacy of Novel Endocrine Therapy in Patients With Metastatic Hormone Sensitive Prostate Cancer, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2025-05-01, completionDateStruct date: 2026-06-30, studyFirstPostDateStruct date: 2024-04-29, lastUpdatePostDateStruct date: 2024-04-29, sponsorCollaboratorsModule leadSponsor name: Peking University First Hospital, class: OTHER, descriptionModule briefSummary: 1. Based on the treatment response and prognosis of mHSPC patients with novel endocrine therapy, a PSMA PET whole-body tumor burden classification was constructed to guide treatment and evaluate prognosis.2. Based on the treatment response and prognosis of mHSPC patients with novel endocrine therapy, a multivariable model will be constructed using quantitative parameters of PSMA PET/CT imaging, pre-treatment gene status, PSA, GS/ISUP and other clinical pathological parameters to further achieve accurate patient classification, guide treatment, and evaluate prognosis., conditionsModule conditions: Prostate Adenocarcinoma, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, interventionModelDescription: Patients With Metastatic Hormone Sensitive Prostate Cancer, will receive pre-therapeutic PSMA PET/CT and post-therapeutic PSMA PET/CT after three-month novel endocrine therapy., primaryPurpose: DIAGNOSTIC, maskingInfo masking: NONE, enrollmentInfo count: 150, type: ESTIMATED, armsInterventionsModule interventions name: PSMA PET/CT, outcomesModule primaryOutcomes measure: rPFS, secondaryOutcomes measure: PSA-PFS, secondaryOutcomes measure: OS, eligibilityModule sex: MALE, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06387212, orgStudyIdInfo id: HUI0001, briefTitle: Clinical Efficacy and Safety of 35 kDa Hyaluronan Fragment (HA35) Injection in the Treatment of Skin Problems., statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2024-05, completionDateStruct date: 2024-05, studyFirstPostDateStruct date: 2024-04-26, lastUpdatePostDateStruct date: 2024-04-26, sponsorCollaboratorsModule leadSponsor name: Nakhia Impex LLC, class: INDUSTRY, descriptionModule briefSummary: To explore the clinical effect and safety of 35 kDa hyaluronic acid fragment ( HA35 ) combined with negative pressure microneedle technology in improving skin problems., conditionsModule conditions: Skin Inflammation, conditions: Cosmetic Skin, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 20, type: ESTIMATED, armsInterventionsModule interventions name: 35 kDa hyaluronan fragment HA35 injection, outcomesModule primaryOutcomes measure: A skin dryness scale, primaryOutcomes measure: A fair or smooth skin scale, primaryOutcomes measure: A skin pore size scale, primaryOutcomes measure: A inflammatory skin thick hardness scale, primaryOutcomes measure: An erythema color and area scale, secondaryOutcomes measure: Self-satisfaction evaluation, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Nahia Impex LLC, city: Ulaanbaatar, country: Mongolia, contacts name: Mizhou Hui, role: CONTACT, phone: 13484005199, email: mizhou.hui@alumni.utoronto.ca, geoPoint lat: 47.90771, lon: 106.88324, hasResults: False
protocolSection identificationModule nctId: NCT06387186, orgStudyIdInfo id: 2023P003233, briefTitle: Leucine Enriched Essential Amino Acid Powder as an Add-on to a Classic Ketogenic Diet in Refractory Epilepsy, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2025-03-31, completionDateStruct date: 2025-03-31, studyFirstPostDateStruct date: 2024-04-26, lastUpdatePostDateStruct date: 2024-04-26, sponsorCollaboratorsModule leadSponsor name: Elizabeth Anne Thiele, class: OTHER, collaborators name: Ajinomoto USA, INC., collaborators name: Ajinomoto Co., Inc., descriptionModule briefSummary: The main purpose of this study is to evaluate the safety and tolerability of a Leucine-Enriched Essential Amino Acid (LEAA) Powder as an add-on to a classic ketogenic diet (KD) in pediatric and adult patients with refractory epilepsy., conditionsModule conditions: Refractory Epilepsy, conditions: Drug Resistant Epilepsy, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 15, type: ESTIMATED, armsInterventionsModule interventions name: Leucine-Enriched Essential Amino Acid powder, outcomesModule primaryOutcomes measure: Number of participants with treatment-related adverse events, secondaryOutcomes measure: Number of participants with improved nutritional status as assessed by weight., secondaryOutcomes measure: Number of participants with improved nutritional status as assessed by body mass index (BMI)., secondaryOutcomes measure: Number of participants with improved nutritional status as assessed by serum ketone and glucose level., otherOutcomes measure: Changes in seizure frequency as assessed by seizure diary., otherOutcomes measure: Changes in behavior and cognitive function as assessed by a questionnaire., otherOutcomes measure: Changes in seizure severity and overall health as assessed by a questionnaire., eligibilityModule sex: ALL, minimumAge: 2 Years, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Massachusetts General Hospital, city: Boston, state: Massachusetts, zip: 02114, country: United States, contacts name: Lydia Tsega, MD, MPH, role: CONTACT, phone: 617-726-6524, email: ltsega@mgh.harvard.edu, contacts name: Carolyn Wilson, role: CONTACT, email: cwilson41@mgh.harvard.edu, geoPoint lat: 42.35843, lon: -71.05977, hasResults: False
protocolSection identificationModule nctId: NCT06387173, orgStudyIdInfo id: 23-001743, secondaryIdInfos id: NCI-2024-01240, type: REGISTRY, domain: CTRP (Clinical Trial Reporting Program), briefTitle: Registry of Patients Undergoing Cryoablation for Early Stage Breast Cancer, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-01-04, primaryCompletionDateStruct date: 2025-01-03, completionDateStruct date: 2099-01-03, studyFirstPostDateStruct date: 2024-04-26, lastUpdatePostDateStruct date: 2024-04-26, sponsorCollaboratorsModule leadSponsor name: Jonsson Comprehensive Cancer Center, class: OTHER, descriptionModule briefSummary: This study evaluates the side effects and outcomes of patients who undergo cryoablation for early stage breast cancer., conditionsModule conditions: Early Stage Breast Carcinoma, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 100, type: ESTIMATED, armsInterventionsModule interventions name: Non-Interventional Study, outcomesModule primaryOutcomes measure: Prospectively track patients who undergo cryoablation for breast cancer and record post-treatment related events., eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: UCLA / Jonsson Comprehensive Cancer Center, status: RECRUITING, city: Los Angeles, state: California, zip: 90095, country: United States, contacts name: Aletta Deranteriassian, role: CONTACT, phone: 310-206-6114, email: ADeranteriassian@mednet.ucla.edu, contacts name: Nimmi S. Kapoor, MD, role: CONTACT, phone: 818-995-8044, email: nskapoor@mednet.ucla.edu, contacts name: Nimmi S. Kapoor, MD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 34.05223, lon: -118.24368, hasResults: False
protocolSection identificationModule nctId: NCT06387134, orgStudyIdInfo id: TCM for early-stage LUAD, briefTitle: Lifei Xiaoji Wan Treatment's of Early-stage NSCLC and Its Impact on the Tumor Microenvironment, statusModule overallStatus: RECRUITING, startDateStruct date: 2022-12-01, primaryCompletionDateStruct date: 2025-01-01, completionDateStruct date: 2025-05-31, studyFirstPostDateStruct date: 2024-04-26, lastUpdatePostDateStruct date: 2024-04-26, sponsorCollaboratorsModule leadSponsor name: Henan University of Traditional Chinese Medicine, class: OTHER, descriptionModule briefSummary: This study evaluated the relationship between the clinical efficacy, histopathological changes and tumor microenvironment of the pharmacopharmacologic Lifei Xiaoji Wan in the treatment of early stage lung adenocarcinoma, and improved high-level clinical evidence and action targets for the prevention and treatment of early stage lung cancer by traditional Chinese medicine, conditionsModule conditions: Early Stage Lung Adenocarcinoma, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: INVESTIGATOR, enrollmentInfo count: 40, type: ESTIMATED, armsInterventionsModule interventions name: Lifei Xiaoji Wan, interventions name: Conventional treatment with Western medicine, outcomesModule primaryOutcomes measure: Lung Cancer Quality of Life Scale (FACT-L), primaryOutcomes measure: TCM symptoms and syndromes, primaryOutcomes measure: Evaluation of tumor efficacy using RECIST criteria to measure changes in tumor body, secondaryOutcomes measure: Tumor markers：CEA, secondaryOutcomes measure: Tumor markers：CA211, secondaryOutcomes measure: Tumor markers：squamous cell carcinoma antigen, secondaryOutcomes measure: Complete blood count: white blood cells, secondaryOutcomes measure: Complete blood count: haemoglobin, secondaryOutcomes measure: Complete blood count: Platelet, secondaryOutcomes measure: Liver function tests: ALT, secondaryOutcomes measure: Liver function tests: AST, secondaryOutcomes measure: Renal function tests: BUN, secondaryOutcomes measure: Renal function tests: Cr, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Mingli Zhao, status: RECRUITING, city: Zhengzhou, country: China, contacts name: Mingli Zhao, MD, role: CONTACT, phone: 0371-66246152, email: 13937159120@163.com, geoPoint lat: 34.75778, lon: 113.64861, hasResults: False
protocolSection identificationModule nctId: NCT06387121, orgStudyIdInfo id: IIT2023060-EC-1, briefTitle: Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Elderly/Unfit Ph- B-ALL, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-15, primaryCompletionDateStruct date: 2026-12-01, completionDateStruct date: 2028-12-31, studyFirstPostDateStruct date: 2024-04-26, lastUpdatePostDateStruct date: 2024-04-26, sponsorCollaboratorsModule leadSponsor name: Institute of Hematology & Blood Diseases Hospital, China, class: OTHER, descriptionModule briefSummary: In the treatment of Ph-negative (Ph-) B-cell acute lymphoblastic leukemia (B-ALL), despite the achievements of chemotherapy and immunotherapy, the therapeutic outcomes are unsatisfactory in elderly or unfit patients. In recent years, tumor immunotherapy has demonstrated a high safety and efficacy profile in refractory Ph- B-ALL patients. These findings suggest that the advancement of immunotherapy application may be an important approach to improve patient survival. In this study, we propose a treatment approach that combines immuno-targeted drugs with low-dose chemotherapy for newly diagnosed elderly or unfit patients with Ph- B-ALL, aiming to enhance the measurable residual disease (MRD)-negative complete remission (CR) rate measured through flow cytometry following induction therapy, reduce the risk of relapse, and ultimately improve patients' overall survival., conditionsModule conditions: Precursor Cell Lymphoblastic Leukemia-Lymphoma, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NON_RANDOMIZED, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 53, type: ESTIMATED, armsInterventionsModule interventions name: Vincristine, interventions name: Cyclophosphamide, interventions name: Dexamethasone, interventions name: Venetoclax, interventions name: Inotuzumab ozogamicin, interventions name: Blinatumomab, interventions name: 6-mercaptopurine, interventions name: Methotrexate, interventions name: Cytarabine, interventions name: Prednisone, outcomesModule primaryOutcomes measure: MRD-negative complete remission rate measured by flow cytometry., secondaryOutcomes measure: Complete remission (CR) rate, secondaryOutcomes measure: Overall survival (OS), secondaryOutcomes measure: Relapse free survival (RFS), secondaryOutcomes measure: Disease-free Survival (DFS), secondaryOutcomes measure: Mortality, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06387108, orgStudyIdInfo id: 24-0045, briefTitle: Evaluation of a Training Course for Educational Professionals, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2025-01, completionDateStruct date: 2025-01, studyFirstPostDateStruct date: 2024-04-26, lastUpdatePostDateStruct date: 2024-04-26, sponsorCollaboratorsModule leadSponsor name: Ludwig-Maximilians - University of Munich, class: OTHER, collaborators name: Prof. OTTO Beisheim Stiftung (Germany), descriptionModule briefSummary: The aim of this study is to evaluate the efficacy of a two-hour online training course on depression and mental health in childhood and adolescence in educational professionals to improve depression and mental health literacy. It will further be investigated whether the course leads to changes in attitudes towards the illness (reduction of stigma) and to an increased behavioural confidence and behavioral change in dealing with pupils with symptoms and illnesses., conditionsModule conditions: Depression, conditions: Depression in Children, conditions: Depression in Adolescence, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: OTHER, maskingInfo masking: NONE, enrollmentInfo count: 42, type: ESTIMATED, armsInterventionsModule interventions name: training course, outcomesModule primaryOutcomes measure: increase in Knowledge, primaryOutcomes measure: decrease in depression stigma, secondaryOutcomes measure: Change in helping behaviour towards pupil, secondaryOutcomes measure: Change in conficende in dealing with pupils with mental health issues, otherOutcomes measure: Evaluation of the training, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: LMU University Hospital (recruitment is conducted online), status: RECRUITING, city: Munich, country: Germany, contacts name: Lisa Feldmann, PhD, role: CONTACT, email: lisa.feldmann@med.uni-muenchen.de, geoPoint lat: 48.13743, lon: 11.57549, hasResults: False